Literature DB >> 26711844

Epilepsy and behavioral changes, type 1 diabetes mellitus and a high titer of glutamic acid decarboxylase antibodies.

Esther Ganelin-Cohen1,2, Dalit Modan-Moses3,4, Rina Hemi5, Hannah Kanety5, Bruria Ben-Zeev6,3, Christiane S Hampe7.   

Abstract

Autoantibodies to the 65 kDa isoform of glutamate acid decarboxylase (GAD65Ab) are associated with a range of clinical disorders, including type 1 diabetes (T1D) and stiff-person syndrome (SPS). In this article we describe a young girl who was diagnosed with T1D at the end of her first year of life and developed drug-resistant epilepsy 18 months later, followed by behavioral disturbances. She was admitted to our center at the age of 5 yr, at which time high GAD65Ab titers were detected in the patient's serum and cerebrospinal fluid (CSF). The titer remained elevated during 19 months of follow-up. Furthermore, GAD65Ab in both serum and CSF showed epitope binding characteristics similar to those observed for GAD65Ab in SPS patients, and GAD65Ab in the serum reduced GAD65 enzyme activity. Our results suggest an association between high GAD65Ab titers and epilepsy in children with T1D. Careful titration and characterization of GAD65Ab regarding inhibition of enzyme activity and epitope specificity may be helpful in identifying T1D patients at risk for neurological complications.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  epilepsy; glutamate decarboxylase antibodies; immune-mediated; pediatric; type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26711844      PMCID: PMC4927419          DOI: 10.1111/pedi.12346

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  35 in total

1.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  An association between type 1 diabetes and idiopathic generalized epilepsy.

Authors:  Dougall McCorry; A Nicolson; D Smith; A Marson; Richard G Feltbower; D W Chadwick
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

3.  Stiff, twitchy or wobbly: are GAD antibodies pathogenic?

Authors:  Angela Vincent
Journal:  Brain       Date:  2008-09-17       Impact factor: 13.501

4.  The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.

Authors:  Marinos C Dalakas
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

5.  Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies.

Authors:  M Vianello; G Keir; B Giometto; C Betterle; B Tavolato; E J Thompson
Journal:  Eur J Neurol       Date:  2005-04       Impact factor: 6.089

Review 6.  GABAergic mechanisms in epilepsy.

Authors:  D M Treiman
Journal:  Epilepsia       Date:  2001       Impact factor: 5.864

7.  Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase.

Authors:  S F Kash; R S Johnson; L H Tecott; J L Noebels; R D Mayfield; D Hanahan; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  Diabetic ketoacidosis and electroencephalographic changes in newly diagnosed pediatric patients.

Authors:  Mark T Mackay; Charlotte Molesworth; Elisabeth A Northam; Terrie E Inder; Fergus J Cameron
Journal:  Pediatr Diabetes       Date:  2015-06-17       Impact factor: 4.866

9.  An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease.

Authors:  Subrata Chattopadhyay; Masumi Ito; Jonathan D Cooper; Andrew I Brooks; Timothy M Curran; James M Powers; David A Pearce
Journal:  Hum Mol Genet       Date:  2002-06-01       Impact factor: 6.150

10.  Association of amino-terminal-specific antiglutamate decarboxylase (GAD65) autoantibodies with beta-cell functional reserve and a milder clinical phenotype in patients with GAD65 antibodies and ketosis-prone diabetes mellitus.

Authors:  Christiane S Hampe; Ramaswami Nalini; Mario R Maldonado; Tyler R Hall; Gilberto Garza; Dinakar Iyer; Ashok Balasubramanyam
Journal:  J Clin Endocrinol Metab       Date:  2006-11-07       Impact factor: 5.958

View more
  2 in total

1.  Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats.

Authors:  Dilidaer Xilifu; Zumulaiti Tuerxun; Buweiayixiemu Nuermaimaiti; Ayinu Aili; Nijiati Rehemu; Huiping Sun; Xiangyang Zhang
Journal:  BMC Pharmacol Toxicol       Date:  2022-09-05       Impact factor: 2.605

Review 2.  The role of inflammation in the development of epilepsy.

Authors:  Amna Rana; Alberto E Musto
Journal:  J Neuroinflammation       Date:  2018-05-15       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.